MedTrace Logo

Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)

NCT04273763 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-05-01

No results posted yet for this study

Summary

Compare the efficacy and safety of Bromhexine Hydrochloride Tablets combined with standard treatment/ standard treatment in patients with suspected and mild, or common novel coronavirus pneumonia (COVID-19).

Random, open, group sequential design.

Conditions

  • Novel Coronavirus Pneumonia
  • 2019-nCoV

Interventions

DRUG

Bromhexine Hydrochloride Tablets

Bromhexine Hydrochloride Tablets

DRUG

Arbidol Hydrochloride Granules

Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection. Arbidol Hydrochloride Granules is recommended but not enforced to use.

DRUG

Recombinant Human Interferon α2b Spray

Standard treatment refers to the latest edition of Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection.

Sponsors & Collaborators

  • Wanbangde Pharmaceutical Group Co., LTD

    collaborator INDUSTRY

  • Second Affiliated Hospital of Wenzhou Medical University

    lead OTHER

Principal Investigators

  • XIAN SHEN, phd · The 2nd Affiliated Hospital of Wenzhou Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-16
Primary Completion
2020-05-10
Completion
2020-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04273763 on ClinicalTrials.gov